

Ref No: AWL/SECT/2021-22/03

February 15, 2022

BSE Limited

Floor 25, P J Towers,

Dalal Street,

Mumbai - 400 001

Scrip Code: 543458

National Stock Exchange of India Limited

Exchange Plaza,

Bandra Kurla Complex.

Bandra (E), Mumbai - 400 051

Scrip Code: AWL

Sub: Newpaper advertisement for the Unaudited Standalone and

Consolidated Financial Results of Adani Wilmar Limited ("the Company")

for the Quarter and Nine months ended 31st December 2021.

Ref: SEBI (Listing Obligations and Disclosure Requirements) Regulations,

2015

Dear Sir / Madam,

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Unaudited Financial Results (Standalone & Consolidated) for the third quarter and nine months ended 31st December 2021 published in the following newspapers:

i)Indian Express (English) dated February 14, 2022

ii) Financial Express (Gujarati) dated February 14, 2022

You are requested to take the same on record.

Thanking you, Yours faithfully,

For Adani Wilmar Limited

Darshil Lakhia

Company Secretary

Memb. No: A20217

Adani Wilmar Ltd. Fortune House

Nr. Navrangpura Railway Crossing

Ahmedabad – 380 009

Gujarat, India

CIN: U15146GJ1999PLC035320

Tel +91 79 2645 5650 Fax +91 79 2645 5621 info@adaniwilmar.in www.adaniwilmar.com

Registered Office: Fortune House, Nr. Navrangpura Railway Crossing, Ahmedabad 380 009, Gujarat, India

SHREE BHAVYA FABRICS LIMITED

CIN: L17119GJ1988PLC011120

Regd. Off.: Survey No. 170, Pirana Road, Piplej, Ahmedabad, Gujarat, 382405 Tel.: +91-79-22133383 • Email: csid7bhavyafabrics@gmail.com

Extract of Unaudited Standalone Financial Results for the Quarter and Nine Months ended on 31st December, 2021

							(0)
							(KS. III Lac
9			Quarter End		Nine Mon	Year Ende	
Sr. No.	Particulars	December 31, 2021	September 30, 2021	December 31, 2020	December 31, 2021	December 31, 2020	March 31, 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total income from Operations	4,289.20	4,455.37	5,236.61	11,375.72	9,493.19	14,534.5
2	Net Profit/(Loss) for the period (before Tax and Exceptional items)	(9.98)	16.34	159.83	21.19	(181.19)	17.9
3	Net Profit/(Loss) for the period (Before Tax and after Exceptional items)	(9.98)	16.34	159.83	21.19	(181.19)	17.9
4	Net Profit/(Loss) for the period (after Tax and Exceptional items)	(5.12)	7.21	155.36	17.11	(187.01)	3.3
5	Total Comprehensive income for the period Profit/(Loss) for the period (After Tax) and other comprehensive income (after Tax)	(5.12)	7.21	155.36	17.11	(187.01)	3.3
6	Paid-up Equity share capital (face value) of Rs. 10/-each share	950.00	950.00	950.00	950.00	950.00	950.0
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)		-		-	-	1,953.3
8	Earnings Per Share (before and after extraordinary items) (of Rs. 10/- each)	(0.05)	0.08	1.64	0.18	(1.97)	0.0

Notes:

Basic and Diluted

Place: Ahmedabad

Date: 14.02.2022

1. The above result is an extracts of the details unaudited Financial Result for the Quarter and Nine Months ended 31st December 2021 filed with the stock exchange under regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015. The full financial result for the Quarter and Nine Months ended on 31st December, 2021 are available on the website of the stock exchange i.e www.bseindia.com and website of the company i.e www.shreebhavvafabrics.com

For, SHREE BHAVYA FABRICS LIMITED Purushottam R. AGARWAL **Managing Director** (DIN: 00396869)

adani wilmar

ADANI WILMAR LIMITED

Registered Office: "Fortune House", Nr Navrangpura Railway Crossing, Navrangpura, Ahmedabad - 380 009. CIN: U15146GJ1999PLC035320 Phone: 079-26455650; Fax: 079-26455621; Email: investor.relations@adaniwilmar.in Website: www.adaniwilmar.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021

(₹ in Crore								
Sr. No.	Particulars	Quarter ended December 31, 2021	Nine months ended December 31, 2021	Quarter ended December 31, 2020				
		(Unaudited)	(Unaudited)	(Unaudited)				
1	Revenue from Operations	14,378.66	39,253.18	10,229.49				
2	Net Profit for the period before taxes and Share in profit/(loss) of Joint Ventures (before Exceptional and/or Extraordinary items)	306.29	760.48	171.33				
3	Net Profit for the period before taxes and before Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	306.29	760.48	171.33				
4	Net Profit for the period after taxes and before Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	220.52	555.12	110.02				
5	Net Profit for the period after taxes and after Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	211.41	569.45	127.39				
6	Total Comprehensive Income for the period [Comprising of Profit for the period (after tax) and other Comprehensive Income (after tax)]	209.69	563.87	127.10				
7	Paid-Up Equity Share Capital (Face Value of ₹ 1 Each)	114.29	114.29	114.29				
8	Earnings Per Share (Face Value of ₹ 1 Each) Basic and Diluted (in ₹) (Not Annualised)	1.85	4.98	1.11				

The aforesaid results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 14, 2022.

The Statutory Auditors have carried out limited review of consolidated financial results of the Company for the quarter and nine months ended on December 31, 2021.

Additional information on Standalone Financial Results is as follows: (₹ in Crores) Nine months Quarter Quarter ended ended ended **Particulars** December December December 31, 2021 31, 2021 31, 2020 (Unaudited) (Unaudited) (Unaudited) Revenue from Operations 13,763.47 38,087.75 10,229.49 172.07 Profit Before Tax 322.34 785.32 Profit After Tax 584.85 240.66 111.02

4 The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 are available on the Stock Exchange websites (www.bseindia.com / www.nseindia.com) and Company's website

For and on behalf of the Board of Directors

Place: Ahmedabad Angshu Mallick Date: February 14, 2022 Managing Director and Chief Executive Officer

ATUL AUTO LIMITED

GUJARAT WATER SUPPLY & SEWERAGE BOARD. GANDHINAGAR Executive Engineer, P.H.W. Dn., Nakhatrana

Tender Notice No. 14 & 6 (3rd Attempt) Year 2021-22 Executive Engineer, Public Health Works Division, Nakhatrana Kutch through

Providing, Supplying Lowering, laying And Jointing Various Dia DI & PVC Pipeline, Construction and Designing of WTP and Storage at various

Varmseda Complex villages, Pump house and compound wall at various headworks, Pumping Machinary For Varmseda Complex RWSS

Augmantation Scheme (Under Nal Se Jal Programme 2020-21 Varmseda

Providing, Supplying Lowering, laying And Jointing Various Dia DI & PVC

Pipeline, Construction Storage at various villages, Pump house and compound wall at various Head works, Pumping Machinery and 5 year O&M

Work For Sutbari RWSS Augmentation Scheme (Under Nal Se Jal

Tender can be downloaded after Dt.11/02/2022 Last Date of online Submission is till Dt.14/03/2022 at 18:00 Hours. Further details are available

Rardingthe problem of drinking water in rural areas, It is requested to,

contact the helpline no. 1916/1800 200 1400 of Gujarat Water Supply &

e-tendering s)lstem in Work

Complex) Ta: Nakhatrana & Bhuj (31rd Attempt)

on the Website http://www.gwssb.nprocure.com

Programme 2021-22) Ta. Abdasa-Kutch

Sewerage Board, Gandhinagar.

DDI/KUTCH/1031/2022

Estimated Cost Rs.7,14,58,750.60 (Tender ID No. 506052)

Estimated Cost Rs. 5,39,48,261.20 (Tender I.D No. 506063)

Reg. Office: Survey No. 86, Plot No. 1 to 4, 8-B, National Highway, Near Microwave Tower, Shapar (Veraval), Dist. Rajkot, Gujarat 360 024 CIN L54100GJ1986PLC016999 I Website: www.atulauto.co.in I E- Mail: info@atulauto.co.in

Extract of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended on December 31, 2021

(Rs. in lacs except per share data) STANDALONE CONSOLIDATED Quarter Ended Nine Months Nine Months Quarter Ended Sr. **Particulars** Ended Ended No. 31.12.2020 31.12.2021 31.12.2020 31.12.2021 31.12.2021 31.12.2021 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Total income from Operation (Net) 9,377 10,171 20,796 10,284 10,171 22,058 Net Profit/(Loss) for the period (1,134)137 (2,549)(1,156)131 (2,593)(before Tax, Exceptional and/or Extra ordinary Items) Net Profit/(Loss) for the period before Tax (1,134)137 (2,549)(1,156)131 (2,593)(after Exceptional and/or Extra ordinary Items) Net Profit/(Loss) for the period after Tax 106 (1,920)(1,975)(852)(881)100 (after Exceptional and/or Extra ordinary Items) Total Comprehensive Income for the period [Comprising Profit/(loss) (846)99 (1,910)(874)118 (1,927)for the period (after tax) and Other Comprehensive Income (after tax)] 1,097 Paid up Equity Share Capital 1,097 1,097 1,097 1,097 1,097 Earning Per Share (Basic and Diluted but not annualised) (3.88)0.47 (8.75)(4.02)0.57 (8.76)(Face value of Rs. 5/-)

The above is an extract of the detailed format of Quarterly Financial Results (Standalone and Consolidated) filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results for the said Quarter and Nine Months end are available on Stock Exchanges Websites: www.bseindia.com and www.nseindia.com. The same is also available on the website of the Company: www.atulauto.co.in

> For and on behalf of Board of Directors of Atul Auto Limited

Jayantibhai J Chandra Chairman & Managing Director (DIN: 00057722)

Date: February 12, 2022 Place : Shapar (Dist. Rajkot)

Flu and influenzas pandem-

ics have ravaged the world

fever, nasal congestion/stuffy

or blocked nose, sore throat

disease can be managed by

symptomatic treatment solu-

tions and red flagging the

vulnerable groups. Simple

medicines like low dose aspi-

rin, statins or anticoagulants

save lives in the high risk car-

diometabolic co morbidities

like diabetes and heart dis-

Now, there is a need to

start living with Covid 19

ens-uring to follow universal

behaviour of masking, air-

ventilation, distancing, and

sanitisation, behave responsi-

bly and stay safe.

eases.



ADVERTORIAL

Living with Covid 19



Dr Shashank R Joshi

MD, DM, FRCP, FICP, FACE, FACP Consultant Endocrinologist, Mumbai Member, Maharashtra COVID-19 Task force

Padma Shri Awardee

unpredictable but is slow mutating new RNA virus which has clearly disrupted the botic complications has been world since 2020. Gazing into increasingly recognized as the future of SARS-CoV-2, an important component of it is predicted that the new this disease associated with variants of concerns due to mutants would not be eradicated anytime soon but may be less severe, though more contagious like Omicron. The new normal has moved from "herd immunity" (a term which has lost its science as the pandemic evolved) to "endemic "word which also needs lots to be thought about.


The evolution of SARS-CoV-2 over the next several months will determine what the end of this global crisis will look like. Will the virus morph into another common cold or evolve into something more threatening such as influenza or worse? As countries lift restrictions, opportunities increase for

SARS-CoV-2 to make sig-nificant evolutionary leaps where it may become a manageable condition in most and protecting the most vulnerable likely to deteriorate. We need to live our lives with Covid 19 with care, caution and precautions without fear and panic.

The novel coronavirus disease of 2019 is associated with significant morbidity and mortality. Our current focus is to save every life from covid 19. Most lives are lost in elderly or unvaccinated population or those who have underlying immunocompromised states or co morbid disorders like SARS-CoV-2 is predictably hypertension, diabetes, heart diseases or kidney or liver issues. The impact of thromhigher risk of death. To add to the burden of thromboembolism, winters are often accompanied with an unusually high occurrence of heart

attacks or strokes. Deaths from heart disease, including sudden deaths, tend to increase rapidly at the onset of winters. The risk of having a heart attack during the winter months is twice as high as during the summers. So, people with cardiometabolic conditions must take utmost care to prevent covid 19 or treat aggressively.

The quest for effective drugs to treat COVID-19 and vaccines to prevent complications has been a priority ever since the outbreak of the disease. Up to now, COVID treatment choices have been inferred from the experience with other coronaviruses or viral infection outbreaks. The options currently being used clinically are categorically divided as antivirals, immunomodulators and other drugs. However, it has been observed that the use of such drugs has shown both, be the key in the first week limited efficacy & specificity against SAR-COV-2 but evidence continues to be generated. Many of these medicines were repurposed and are still under investigation.



'Lone Coronavirus battling against the host of antibodies.'

Need of the Hour: Boost Immunity since 1918 till date. Covid 19 had also seen waves and strains evolve which has seen it evolve from a life-threatening pneumonia like disease from the Wuhan strain till the current less severe Omicron strain which is flu like syndrome in most people now. Omicron related tsunamic like wave is less severe but highly contagious. The manifestations of Omicron are essentially an upper airway disease which is "nose" and "throat" covid. They are **Rohit Shelatkar**

with pain, cough, headache, Vitabiotics Ltd. UK bodyache, tiredness(fatigue), Heads the international business myalgia (muscle pain) and team along with his participation many others. The lung covid in the Product Formulations and which was seen in the Delta Regulatory Affairs. strain can still rarely exist of-For those who had hoped ten may have loss of smell and that 2021 would be the year taste should never be missed. that put the pandemic in Monitoring temperature and the past tense, it was a harsh oxygen saturation will always reminder that it is still very much present. Rather than particularly. Symptomatic laying plans to return to the treatment is the key with an-'normal' life we knew before tipyretics, anti-inflammatory, the pandemic, 2022 is the antihistamines and simple year the world must come immunity stimulating mito terms with the fact that cronutrients. So current mild

> The emergence of the Omicron variant last November highlighted the ongoing challenges of life with SARS-CoV-2. The transmission rate increases with each new emerging variant & hence vaccine is only partially effective method of protection against the new mutants.

SARS-CoV-2 is here to stay.

B Pharmacy, MSc. Pharmacology,

Sr. Vice President, Director,

While COVID-19 is prevalent, the combined use

and antivirals might be the optimal therapy for the disease. The emergence of affordable and powerful oral anti-COVID-19 drugs and the increased uptake of vaccination will bring hope for the end of the COVID-19 pandemic.

It takes years to develop antiviral drugs & looking at repurposing easilyaccessible which treat COVID symptoms. The need of the hour is to look at therapies that can be taken at home in tablet form to reduce hospital load. Knowledge & detailed science behind use of aspirin & promethazine in treating flu like symptoms backed by clinical evidence is sufficiently available.

Micronutrient have potential roles in interfering with virus at the entry site, and inhibiting activities of replication cycle of severe acute respiratorysy syndrome coronavirus Micro-nutrient also have immunomodulating, antiinflammatory, antioxidant, and antiviral properties. Therefore, micronutrients are consequently a promising alterative nutritional approach to combat COVID-19.

Vitamin D supplementation is safe and effective up to 4,000 IU in reducing virus replication and conof immunomodulatory or trolling the cytokine storm.

anti-inflammatory agents In COVID, vitamin C up to 1500 mg provides optimum in COVID-19.Vitamin B3 not only helps to build and maintain a healthy immune system but it could potentially prevent or reduce COVID-19 symptoms or treat SARS-CoV-2 infection. Zinc has immunomodulatory, antiviral & anti-inflammatory responses and supplementing 15-30 mg Zinc per day in COVID infected is effective. Selenium and Iodine has beneficial effects on immunity, with a dose more than 100 µg per day.

> The COVID-19 pandemic is still severe, and most of the drugs currently for COVID-19 are not designed specifically against SARS-CoV-2. The combination of Aspirin, Promethazine and micronutrients inhibits viral proliferation in early stage of COVID-19 thus preventing subsequent severe complications. Clinical evidence suggests that Aspirin, promethazine and micronutrients can shorten the recovery time of COVID-19 symp-

Need of the hour with omicron variant is to boost immunity of those vaccinated & unvaccinated as emerging variants tend to cause mild illness. Clearly better vaccines will take years to develop and right now what we need is widely available & safe, affordable therapies.

Issued in Public Interest by Vitiabiotics Ltd.

OZONE WORLD LIMITED 0.00 30.19 33.94 64.41 (7.25) 18.82 9.08 34.76 Total Income from operations Not Profit / (Loss) from ordinary Net Protit / (Lose) from ordinary activities after tax Total Comprehensive income for the period (Comprising protit for the period and Other Comprehensive income for the period) after tax Equity Share Capital Earnings Fer Share (of Rs. 101- each) Basis: (7.25) 18.82 9.08 34.76 369.91 369.91 369.91 369.91 (0.20) 0.51 0.51 0.25 0.25 0.94

O SATYA Micro Capital Ltd. SATYA Micro Capital Limited

(CIN: U74899DL1995PLC068688)

Registered Office Address: 519, 5th Floor, DLF Prime Towers, Okhla Industrial Area, Phase - I, New Delhi-110020, India, Phone No. 011- 49724000, website : www.satyamicrocapital.com

EXTRACT OF THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2021

S. No.	Particulars	Quarter Ended December 31, 2021	Year Ended March 31, 2021
		Unaudited	Audited
1	Total Income from operations	1.056.24	2,672.18
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	51.64	151.06
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	51.64	151.06
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	39.76	162,17
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	39.39	101.88
6	Paid up Equity Share Capital	460.01	458.50
7	Reserves (excluding Revaluation Reserve)	250.96	118.83
8	Securities Premium Account	3,475,41	3,466,96
9	Net worth	4.186.38	4.044.29
	Paid up Debt Capital/ Outstanding Debt	17,783,18	11,270,76
11	Outstanding Redeemable Preference Shares	NI	Nil
12	Debt Equity Ratio (no. of times)	4.25	2.79
13	4 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -		-
	1. Basic (EPS)*:	0.87	2.57
_	2. Diluted (DPS)*:	0.86	2.53
14	Capital Redemption Reserve	NI	Nil
15	Debenture Redemption Reserve	NI	Nil
	Debt Service Coverage Ratio	NA.	N.A.
17	Interest Service Coverage Ratio	1.11	1.12

- 1 The unautified standaione financial results for the quarter and nine months ended December 31 (2021) have been reviewed by the Audit Committee and threather approved and taken on record by the Bloard of Directors at their meetings held on February 12, 2022. The unautified standaione financial results was also limited reviewed by the statutory audition of the Company.

 1 The above is an extract of the detailed format of unaudited standaione financial results for the quarter and rine months ended Becember 31,2021 filled with the Stock Exchanges under Regulation \$2 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited weather of the committee of the second of the second second of the second
- This extract of unautified standations financial results for the quarter and nine months ended December 31,202 has been proposed in accordance with the requirement of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with circular no. SEBIHOTIONS/CR/2021/0000000837 dated October 7, 2015.
- Utilization hashes a second or the second of the second of

Vivek Tiwari Managing Director, CEO & CIO Place : New Delhi Date: February 12, 2022

adani wilmar

ADANI WILMAR LIMITED

Registered Office: "Fortune House", Nr Nevrangpura Railway Crossing, Navrangpura, Ahmedabad - 380 009, ClN : U15146GJ1999PLC035320 Phone: 079-26455650; Fax: 079-26455621; Email: investor.relations@adaniwilmar.in

(f in Crore							
Sr. No.	Particulars	Quarter ended December 31, 2021	Nine months ended December 31, 2021	Quarter ended December 31, 2020			
		(Unaudited)	(Unaudited)	(Unaudited)			
1	Revenue from Operations	14,378.66	39,253.18	10,229.49			
2	Net Profit for the period before taxes and Share in profit/(loss) of Joint Ventures (before Exceptional and/or Extraordinary items)	306.29	760.48	171.33			
3	Net Profit for the period before taxes and before Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary Items)	306.29	760.48	171.33			
4	Net Profit for the period after taxes and before Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	220.52	555.12	110.02			
5	Net Profit for the period after taxes and after Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	211.41	569.45	127.39			
6	Total Comprehensive Income for the period [Comprising of Profit for the period (after tax) and other Comprehensive Income (after tax)]	209.69	563.87	127.10			
7	Paid-Up Equity Share Capital (Face Value of \$1 Each)	114.29	114.29	114.29			
8	Earnings Per Share (Face Value of ₹1 Each) Basic and Diluted (in ₹) (Not Annualised)	1.85	4.98	1,11			

The Statutory Auditors have carried out limited review of consolidated financial results of the Company for the quarter and trian months ended on December 31, 2021.

Additional information on Standalone Financial Results is as follows: (C in Cross)

Recultal tas #70 (# in Corres)

Quarter ended December 31, 2021

Quadited December 31, 2021

Quadited December 31, 2021

Quadited) (Unsudited) (Unsudited)

1376347 38,087.75 10,229.49

322.34 783.32 172.07

240.66 584.85 111.02

The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and nine menths ended on December 31, 2021 filed with the Stade Exhanges under Regulations, 30 fits des Edil Listing Obligations and Disclasious Requirements, Regulations, 2015. The full format of the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 are wealibable on the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 are wealibable on the Standalone and Company's website wave advantaged to the consolidation of the Standalone and Company's website wave advantaged to the standalone and the Standalone and Company's website wave advantaged to the Standalone and Company's wa

Place: Ahmedabad Date: February 14, 2022

Angshu Mallick Managing Director and Chief Executive Officer

Crompton

PUBLIC NOTICE

is commune Exerticeas United requests its shareholders to remail address and molecular services belowing procedure. Contact Company's Registers and Share Transfer Agent, strends of the Company's Registers and Share Transfer Agent, strends critical below. The community of the community of the folio no., nime of the Member second doesy of share PAN Conta and Address of the Community of the Register/update their amail addresses and mobile numbers with That relevant dispositions through their of from Stautholders whose email address and mobile numbers.

Alembic

ALEMBIC LIMITED

CIN: L25100GJ1907PLC000033
Regd.Office: Alembic Road, Vadodara 390 603
Tel: 0285-2280550
Website: www.dembidimited.com
Email: alembic investore@alembic.co.in

Extract of Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31" December, 2021

		(₹ in Lacs e	xoept per share data				
	Consolidated						
	Quarter Ended	Quarter Ended	Nine Months Ende				
Particulars	31.12.2021	31.12.2020	31.12.2021 Unaudited				
	Unaudited	Unaudited					
Total Income from Operations	2,106	1,750	14,476				
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	430	580	9,204				
Net Profit for the period before Tax (after Exceptional and/or Extraordinary items	430	580	9,204				
Net Profit for the period after Tax (after Exceptional and/or Extraordinary items	412	487	8,154				
Total Comprehensive Income for the period	12,625	7,575	31,937				
Equity Share Capital	5,136	5,135	5,136				
Earning Per Share (of ₹ 2/- each) Basic & Diluted	2.02	3.33	8.61				
Note 1. Standalone detalls:							
Particulars	Quarter Ended	Quarter Ended	Nine Months Ended				
1 miscama	31.12.2021	31.12.2020	31.12.2021				
	Unaudited	Unaudited	Unaudited				

The above is an extract of the detailed format of financial results flied with the Stock Exchanges under Regulation 33 of the SEB (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the Company's website at www.alembiclimited.com and on Stock Exchange's website at www.nsorindls.com and www.bsinindls.com

PUBLIC NOTICE

કોટક મહિન્દ્રાં બેંક લિમિટક www.kotak.co રજી. મોરિકા રહ મહિતા, તો નાત, જ ખીત, પહેલ કહ્યું કેમ્પ્યોર, બંલ (પુ), મુંબઈન્સ, કોમ્પીટ મોરિકા રહેલ પરિકાર્ત, તો, પહેલ કહ્યું, તે, પહેલ કહ્યું, તે, મુંબઈ ને માને કર્યા પ્રતિકાર કોંદ્ર પરિકાર તે, પદ, પરિકારીને પાંત્ર, પતારા તો, તે, પાંત્ર પર, પાંત્ર (પુ), મુંબઈન્સ માને પાંત્ર હેલાતારીને તે મેરામાં રિલ્લા મહુવાર લોનાલ દાગિનાની પાત્રે મોરનાની લીતા સુધિકા તે તર્તી, ઉત્સ્વારની પાત્ર તાત્ર તેના માને બાલે કેસ માને આ લીતાની પાત્ર પ્રતિકારની પાત્ર તેના તેના કોંદ્ર તાત્ર પાત્રી હોતાની પાત્ર પાત્રી હોતાની પાત્ર પાત્રી હોતાની પાત્ર પાત્ર હોતાની પાત્ર પાત્રી હોતાની હો

बसङ्ग रह वेनाना टा॰	।। तथा अङ तिकानी हराए	તેના નિકળતા બાકી લ્ફેટાંની રકમની paરવામાટે નક્કી કરેલ છે.	पसूरात	भादे क्षेत्र पार	(desamine)	भीश्य शर्भ
ોપીએસી	Midi	ઉદ્યારકર્તાનું નાગ	2379	580	tivii .	સોસ વ સામ ૧
A35333	28134	અન્દ્રલસમદ એન. શેખ	gy.	બરોડા	અંકલેશ્વર	24.
400240	W4303	ઉંક્રકદભાઈ અમધાભાઈ વસાવા	ajv.	બરોડા	અંકલેશ્વર	39.
44840¥	911/23	ઉંકકદભાઈ અમધાભાઈ વસાવા	ગુજ.	બરોડા	sisches	24.
восчка	92390	ઉંક્રક્ટભાઈ અમધાભાઈ વસાવા	ay.	બરોડા	અંકલેશ્વર	40.
013414	118848	ખેર નિલેશભાઈ જગદીશભાઈ	yv.	રાજકોટ	(अडिताल गर	10.
210010	20822	અર્પણ ક્રાંતિલાલ જોપી	3j¥.	બરોડા	ભરૂપકેસી	wo.
411901	4024	અર્પણ ક્રાંતિલાલ જોપી	ગુજ.	બરોડા	ભરૂપકેસી	Yu.
028500	123914	મુ:હફાર એંચુલ પટેલ	214.	બરોડા	ભરૂપ દેશી	19.
001848	118468	રતનબેન મહેરાભાઈ કોળી	2JY.	બરોડા	ભરૂપ દેશી	20.
090386	109240	સોની પ્રિકલ કલ્પેશભાઈ	ay.	બરોડા	ભરૂપ દેશી	37.
028804	123440	ભલોડીયા સાગર	374.	બરોડા	બીપીસી રોક	w3.
OKOOKS	110002	યાવડા રૂપાભાઈ ગોસભાઈ	ay.	शुक्त	5dl2PIPI	37.
3220C¥	nacca	ગો. મુસ્તકીય મો. કાસીંગ ફાશીવાલા	ay.	अंदर	5disHPi	39.
0<058K	110128	नवापश्च तुमत वातुमार्ग	ગુજ.	अंदर	5di2PiPi	90.
127055	44408	આદીશ પરેશભાઈ પટેલ	3Y.	अंदरत	होरड कार्डस	420.
#8.52CO	45009	રાયમા પશભાઈ જમંતિભાઈ	ay.	зірізки	મહિલ્લગર	34.
010050	114302	30ગીમાં આપેશ પંચાલ	ay.	зірізки	મકેસાણા	92.
*31202	42040	પંચાલ પ્રતિક રાજેશભાઈ	agv.	зірізки	મહેરાણા	857
W410CY	42010	પટેલ પંકપકુષાર બધુભાઈ	ay.	зірізки	મહેરાણા	¥04.
644880	233¥1	પટેલ પંક્રજકુમાર બચુભાઈ	agy.	зірізки	મહેરાણા	422.
434483	65365	પદાણ આવેનાબીબી યુસ્કૂબાન	37.	зірізки	મકેસાણા	54.
248630	158345	રાંજયભાઈમાંતિભાઈરાઇકીયા	37.	રાજકોટ	મોરબી	109.
222264	53595	દિપક્રમુગાર ગિરધરભાલ મેવાડા	34.	зірізки	पालनपुर	¥9.
058353	111004	जिल्ह्यामार्थ सीटीलार्ध सेवा -	37.	शक्षकीर	રેસકોર્સ	39.
029924	183480	વિજલભાઈ શીદી ભાઈ છે થા	37.	शक्ष्मेट	રેસકોર્સ	90.
****	2040c	સાલીબએફગદ ફારૂકએફગદ સૈયદ	37.	зірізин	સ્ટોશનાઈટ	wo.
202700	24493	કંદોઈ નીતુબેન એન.	ay.	બરોડા	पडशाजी	18.
ARCSSA	43304	રાજુભાઈવી. ખટીક	gy.	બરોડા	तरशाणी	29.
007160	106544	ભરતભાઈ ગોબરભાઈ બાબદીયા	37.	शुक्त	વરાછા રોક	110.
068884	103934	धर्मेन्द्रलाएँ ट्रुलालाएँ कुछडीया	37.	sisu	वशकाशेड	141.
<*ecoo	68050	દાર્મેશભાઈ દિલીપભાઈ સુબા	ay.	भुरत	વસભારોક	49.
358515	93980	દિનેશભાઈ ભીખાભાઈ મેંદાપરા	34.	Sign	વરાછા રોક	122.
04550	119810	કલ્પેશ કાનજીભાઈ વડોદરીયા	37.	अंदर	पशका शेड	114.
ce3999	ccsan	કાપડીયા દિપેશ મનુભાઈ	37.	शुक्त	पशका शेड	23.
exesxu	3040K3	अलिप्रक्रभार	27.	5154	વરાણા રોક	33/

૪૪૧૪૫ ૧૦૩૦૪૩ મનિષ્ધુમાર ૮૮૮૦૦૩ ૦૮૫૫૦ સુખામાર્યમેકુરમાર્યખટાગ્રા યુપ. સુરત વરાઇ રોડ ૧૪. પરોક્ત જણાવેલ સોનાના દાગીનાની જાહેર હરાજી **કોટક મહિન્દ્રા બેંક લિપિટેકની સંબંધિ**

Place: Vadodara Date: 14th February, 2022

EQUITAS HOLDINGS LIMITED

Regd. Office: 410A, 4th Floor, Spencer Plaza, Phase II, No.769, Mount Road, Anna Salai, Chennai CIN: L65100TN2007PLC064069 | Ph: 044 4299 5000 | www.equitas.in

Statement of Standalone & Consolidated Unaudited Financial Results for the Three Months and Nine months period Ended 31 December 2021

		Standalone					Consolidated (₹ in Lakhs)			
SI. No.	Particulars	Three Months Ended Dec 31, 2021	Three Months Ended Dec 31, 2020	ed Ended	led Year Ended	Three Months Ended Dec 31, 2021	Three Months Ended Dec 31, 2020	Nine Months Ended Dec 31, 2021	Year Ended Mar 31, 2021	
		Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited	
1	Total Income from Operations	494.86	16,260.35	1,469.72	17,772.88	104,374.94	115,243.52	299,171.51	382,069.13	
2	Net Profit for the Period / Year Before Tax,	1,573,780	220000000000000000000000000000000000000	3552 856555	0.004.0000400	S-7000000000000000000000000000000000000	100000000000000000000000000000000000000		03:00(00:00)	
	Exceptional and / or Extraordinary items	(200.91)	16,145.57	511.31	16,944.11	13,037.21	30,806.51	20,716.28	65,609.21	
3	Net Profit for the Period / Year Before Tax	5.000000	20,000,000	5350,000	94505000	1715-1755		500000000000000000000000000000000000000	2011/0000	
	after Exceptional and / or Extraordinary items	(6,320.07)	16,145.57	(5,607.85)	16,944.11	6,918.05	30,806.51	14,597.12	65,609.21	
4	Net Profit for the Period / Year After Tax	15:50×111×13	10010000	P. S.	110000000000000000000000000000000000000	150000000	53535657556	250000000000000000000000000000000000000	2000 000000	
	after Exceptional and / or Extraordinary items	(6,275.70)	14,231.89	(5,755.94)	14,695.12	3,514.01	25,145.11	9,277.59	51,379.53	
5	Total Comprehensive Income for the Period / Year	20-50 (Vestical)	20,700,200,000		100000000000000000000000000000000000000	35.500.030	40070000000	565,000,000	100000000000000000000000000000000000000	
	[(comprising profit / (loss) for the period (after	0000000000	57/01/51/01/52/5	MONTOR-1-100	20,000,000	000000000000000000000000000000000000000	100000000000000000000000000000000000000	1010075100771	200000000	
	tax) and other comprehensive income (after tax)]	(6,276.82)	14,231.93	(5,759.31)	14,695.60	3,385.22	26,170.80	8,930.91	51,779.62	
6	Equity Share Capital	34,179.01	34,179.01	34,179.01	34,179.01	34,179.01	34,179.01	34,179.01	34,179.01	
7	Other Equity	333000000			144,199.00	0007.000000	000000000000000000000000000000000000000		273,448.39	
8	Earnings Per Share (EPS) for Continuing and				300				123	
	discontinued Operations, (not annualised)									
(i)	Basic (₹)	(1.84)	4.16	(1.68)	4.30	1.03	7.36	2.71	15.03	
(ii)	Diluted (₹)	(1.84)	4.16	(1.68)	4.30	1.03	7.36	2.71	15.03	
_		1	,,,,,	4						

NOTES:
The above is an extract of the detailed format of the three months / nine months ended Financial Results filed with the Stock Exchanges under Reg the SEBI (Justing Obligations and Disclosure Requirements) Regulation, 2015. The full format of three months / nine months ended Financial examinations are under the second of the Company's website www.equ. examilation on the websites of the Stock Exchanges viz. www.nesfendia.com and view.usberdial.com and viso on the Company's website www.equ.

ATUL AUTO LIMITED

Reg. Office: Survey No. 86, Plot No. 1 to 4, 8-8, National Highway, Near Microwave Tower, Shapar (Veraval),
Dist. Rajkot, Gujarat 360 024 CIN L54100G/1986PLC016999 | Website: www.atulauto.co.in | E-Mail: info@atulauto.co.in



Extract of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months e (Rs. in lacs except per share da STANDALONE CONSOLIDATED

140.		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Total income from Operation (Net)	9,377	10,171	20,796	10,284	10,171	22,058
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extra ordinary Items)	(1,134)	137	(2,549)	(1,156)	131	(2,593)
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extra ordinary Items)	(1,134)	137	(2,549)	(1,156)	131	(2,593)
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extra ordinary Items)	(852)	106	(1,920)	(881)	100	(1,975)
5	Total Comprehensive Income for the period [Comprising Profit/(loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(846)	99	(1,910)	(874)	118	(1,927)
6	Paid up Equity Share Capital	1,097	1,097	1,097	1,097	1,097	1,097
7	Earning Per Share (Basic and Diluted but not annualised) (Face value of Rs. 5/-)	(3.88)	0.47	(8.75)	(4.02)	0.57	(8.76)

For and on behalf of Board of Directors of Atul Auto Limited



Date : February 12, 2022 Place : Shapar (Dist. Rajkot)